Frontline stock price traded at $22

Frontline stock price traded at $22.45 in the last session, showing a 1.38% intraday decline amid broader shipping sector volatility. Analysts note that strong tanker demand and resilient freight rates could push Q3 earnings higher, potentially supporting a rebound to the $24.00 level. According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previously treated metastatic head and neck cancers. While Frontline currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Sector sentiment remains constructive, supported by firm time charter equivalents across major tanker classes.